Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 11, 2025
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program
GlobeNewswire
·
March 11, 2025
Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, …
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
GlobeNewswire
·
March 11, 2025
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMR AMR is a leading cause of kidney transplant loss, with approximately ~23k patients living with all forms of AMR in the U.S1 …
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
GlobeNewswire
·
March 11, 2025
CAMBRIDGE, Massachusetts, March 11, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in …
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 11, 2025
Accelerated fourth quarter sales growth to 13.5% Fourth quarter gross margin expanded 310 bps and adjusted gross margin* expanded 230 bps Fourth quarter cash from operations of $19.3 million increased 86.3% Provides full-year 2025 financial guidance …
BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
GlobeNewswire
·
March 11, 2025
Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating income and Adjusted EBITDA margin guidance Company …
Aurora Spine to Attend the American Academy of Orthopaedic Surgeons Annual Meeting
GlobeNewswire
·
March 11, 2025
Carlsbad, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced that …
The Joint Corp. Names SVP Development
GlobeNewswire
·
March 11, 2025
SCOTTSDALE, Ariz., March 11, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic® network, welcomes Craig Sherwood as the company’s new Senior Vice President of …
Interim analysis of 1-level BAGUERA®C IDE study meets threshold for non-inferiority
GlobeNewswire
·
March 11, 2025
Interim analysis of 1-level BAGUERA®C IDE study meets threshold for non-inferiority Geneva, March 11, 2025 – Spineart, a fast-growing company in spine surgery innovation, today announces that it has completed a planned interim analysis for its 1-level …
PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
GlobeNewswire
·
March 11, 2025
PETACH TIKVA, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the successful completion of enrollment in the SHIELD II …
Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device
GlobeNewswire
·
March 11, 2025
--Anthem Blue Cross Blue Shield approves claim for PoNS Device at out-of-network adjusted list price-- --Provides further validation of PoNS pricing-- NEWTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius …
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025
GlobeNewswire
·
March 11, 2025
Company to present clinical results from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader MRT-6160 and Phase 1/2 study of MRT-2359 in MYC-driven solid tumors Conference call and webcast planned for 8 a.m. ET on March 20, 2025 BOSTON, March 11 …
Tilray Medical Launches Tilray Craft: Introducing High THC, High Terpene Genetics to the German Medical Cannabis Market
GlobeNewswire
·
March 11, 2025
NEUMÜNSTER, Germany, March 11, 2025 (GLOBE NEWSWIRE) -- Tilray Medical (“Tilray”), a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY) and a global leader in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare …
Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th
GlobeNewswire
·
March 11, 2025
CHATHAM, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman M.D., …
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewswire
·
March 11, 2025
Topline data expected in second half of 2025 to support potential sNDA submission for label expansion of IGALMI® in the home setting Company has $35M of cash following closing of recent equity financing NEW HAVEN, Conn., March 11, 2025 (GLOBE NEWSWIRE) -- …
Paw-litics Heats Up on the Hill: Cutest Pets on Parliament Hill Contest Returns
GlobeNewswire
·
March 11, 2025
TORONTO, March 11, 2025 (GLOBE NEWSWIRE) -- The Canadian Animal Health Institute (CAHI) is excited to launch the 3rd Annual Cutest Pets on Parliament Hill photo contest, a fan-favourite among the pet-owning denizens of the halls of power in Ottawa! This …
La campagne « poil » itique se met en branle sur la Colline : Retour du concours « Les animaux de compagnie les plus mignons sur la Colline du Parlement »
GlobeNewswire
·
March 11, 2025
TORONTO, 11 mars 2025 (GLOBE NEWSWIRE) -- L’Institut canadien de la santé animale (ICSA) est heureux de lancer le troisième concours annuel de photos « Les animaux de compagnie les plus mignons sur la Colline du Parlement », un concours très prisé par les …
Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights
GlobeNewswire
·
March 11, 2025
CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectively Over 5,000 patients treated to date Initiated commercial production of CARVYKTI® at a Novartis production facility Spain's …
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 11, 2025
– Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half and the second half of 2025, respectively – – Plan to …
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
GlobeNewswire
·
March 11, 2025
- Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from treatment-resistant depression - VLS-01 is being …
Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 11, 2025
Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS) disorders Continued momentum in the Phase 2a trial of RAP- …